Biosimilars Boost Offsets Generics Slide For Sandoz

Sales Remain Steady In 2020 Despite Turbulence Of COVID-19

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

Rocks Beach Balanced Offset
Biopharmaceuticals growth balanced out a decline in retail generics for Sandoz • Source: Shutterstock

Growth of a fifth for Sandoz’ Biopharmaceuticals business – driven by the continued success of its biosimilars portfolio, in Europe and elsewhere – has offset the negative impact of COVID-19 on the company’s retail generics business in 2020, allowing the Novartis off-patent unit to report sales that were steady compared to the previous year.

The company’s $9.646bn turnover total represented a 1% decline as reported, but was flat at constant currencies, with overall volume...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business